BCRX

Biocryst Pharmaceuticals INC

+$707.5M

Net Activity

Institutions Holding

300

Popularity Rank

#1979

Avg Weight

0.19%

Total Value

$2.4B

Ownership Trend

300 institutions currently hold BCRX, with 184 net buyers and 119 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

119

Net Buying Institutions

184

Key Holders

View all 300 holding institutions

Quarterly Activity

Recent Activity

+$1.7B

Total Buy Value

$491.1M

Total Sell Value

New buy67
Trim76
Add117
Sold out43

184

Net Buyers

119

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding BIOCRYST PHARMACEUTICALS INC (BCRX)?
Major stakeholders currently include BlackRock, Inc. ($215.6M), Ra Capital Management, L.p. ($150.7M), Deerfield Management Company, L.p. ($143.2M). Based on the latest 13F filings, there are a total of 300 tracked investment funds and institutions maintaining positions in BCRX.
What is the overall institutional sentiment toward BCRX recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $707.5M, driven by 184 managers accumulating shares while 119 reduced their exposure.
Which institutions have been selling or reducing their BCRX positions?
In the latest period, 76 funds trimmed their holdings, and 43 managers completely exited their positions. The aggregate reported sell value was $491.1M.
Are there any notable investors adding BCRX to their portfolios?
Yes, buying activity remains notable. 67 institutions opened new positions in {ticker}, and 117 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.7B.

Related Stocks